HEMAB THERAPEUTICS HOLDINGS INC (COAG)

NASDAQHealth CareBiotechnologySnapshot 2026-10-16

$30.07-7.53%

Close 2026-10-16 · 1-day change

Read the published Living FV report summary

Investment OutlookAs of Oct 16, 2026

What could strengthen or challenge HEMAB THERAPEUTICS HOLDINGS INC’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Living FV™

Living Fair Value by QuarterlyIQ

A valuation that evolves as the business changes.

A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.

View Living FV report and workflow

What the Thesis Depends On

Three key conditions need to be met for the investment thesis to play out.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Sufficient cash reserves to fund operations	A supporting condition in HEMAB THERAPEUTICS HOLDINGS INC's published investment case. The stated target is >= $100 million in cash by FY26.	Intact	cash reserves fall below $50 million	Cash and cash equivalents: $237.366M FY2026-Q2; GAAP. Published target: >= $100 million in cash by FY26. Target period is not explicitly aligned with this observation. Source date unavailable237,366,000 USD · source valueSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_balance_sheet. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Advancement of HMB-001 and HMB-002 in clinical trials	Hemab has multiple clinical catalysts in its pipeline.	Improving	no significant trial advancement by FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Positive market reception of clinical data	A supporting condition in HEMAB THERAPEUTICS HOLDINGS INC's published investment case. The stated target is >=70% positive analyst sentiment by FY26.	Intact	analyst sentiment falls below 40%	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenueUnavailable

Unavailable → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-27	Unavailable	Unavailable	3 / 0
2026-07-28	Unavailable	Unavailable	3 / 0
2026-07-29	Unavailable	Unavailable	3 / 0
2026-07-30	Unavailable	Unavailable	3 / 0
2026-07-31	Unavailable	Unavailable	3 / 0
2026-08-01	Unavailable	Unavailable	3 / 0
2026-08-02	Unavailable	Unavailable	3 / 0
2026-08-03	Unavailable	Unavailable	3 / 0
2026-08-04	Unavailable	Unavailable	3 / 0
2026-08-05	Unavailable	Unavailable	3 / 0
2026-08-06	Unavailable	Unavailable	3 / 0
2026-08-07	Unavailable	Unavailable	3 / 0
2026-08-08	Unavailable	$0	3 / 5
2026-08-09	Unavailable	$0	3 / 5
2026-08-10	Unavailable	$0	3 / 5
2026-08-11	Unavailable	Unavailable	3 / 0
2026-08-12	Unavailable	Unavailable	3 / 0
2026-08-13	Unavailable	$0	3 / 5
2026-08-14	Unavailable	Unavailable	3 / 0
2026-08-15	Unavailable	Unavailable	3 / 0
2026-08-16	Unavailable	Unavailable	3 / 0
2026-08-17	Unavailable	Unavailable	3 / 0
2026-08-18	Unavailable	Unavailable	3 / 0
2026-08-19	Unavailable	Unavailable	3 / 0
2026-08-20	Unavailable	Unavailable	3 / 0
2026-08-21	Unavailable	Unavailable	3 / 0
2026-08-22	Unavailable	Unavailable	3 / 0
2026-08-23	Unavailable	Unavailable	3 / 0
2026-08-24	Unavailable	Unavailable	3 / 0
2026-08-25	Unavailable	Unavailable	3 / 0
2026-08-26	Unavailable	Unavailable	3 / 0
2026-08-27	Unavailable	Unavailable	3 / 0
2026-08-28	Unavailable	Unavailable	3 / 0
2026-08-29	Unavailable	Unavailable	3 / 0
2026-08-30	Unavailable	Unavailable	3 / 0
2026-08-31	Unavailable	Unavailable	3 / 0
2026-09-01	Unavailable	Unavailable	3 / 0
2026-09-02	Unavailable	Unavailable	3 / 0
2026-09-03	Unavailable	Unavailable	3 / 0
2026-09-04	Unavailable	Unavailable	3 / 0
2026-09-05	Unavailable	Unavailable	3 / 0
2026-09-06	Unavailable	Unavailable	3 / 0
2026-09-07	Unavailable	Unavailable	3 / 0
2026-09-08	Unavailable	Unavailable	3 / 0
2026-09-09	Unavailable	Unavailable	3 / 0
2026-09-10	Unavailable	Unavailable	3 / 0
2026-09-11	Unavailable	Unavailable	3 / 0
2026-09-12	Unavailable	Unavailable	3 / 0
2026-09-13	Unavailable	Unavailable	3 / 0
2026-09-14	Unavailable	Unavailable	3 / 0
2026-09-15	Unavailable	Unavailable	3 / 0
2026-09-16	Unavailable	Unavailable	3 / 0
2026-09-17	Unavailable	Unavailable	3 / 0
2026-09-18	Unavailable	Unavailable	3 / 0
2026-09-19	Unavailable	Unavailable	3 / 0
2026-09-20	Unavailable	Unavailable	3 / 0
2026-09-21	Unavailable	Unavailable	3 / 0
2026-09-22	Unavailable	Unavailable	3 / 0
2026-09-23	Unavailable	Unavailable	3 / 0
2026-09-24	Unavailable	Unavailable	3 / 0
2026-09-25	Unavailable	Unavailable	3 / 0
2026-09-26	Unavailable	Unavailable	3 / 0
2026-09-27	Unavailable	Unavailable	3 / 0
2026-09-28	Unavailable	Unavailable	3 / 0
2026-09-29	Unavailable	Unavailable	3 / 0
2026-09-30	Unavailable	Unavailable	3 / 0
2026-10-01	Unavailable	Unavailable	3 / 0
2026-10-02	Unavailable	Unavailable	3 / 0
2026-10-03	Unavailable	Unavailable	3 / 0
2026-10-04	Unavailable	Unavailable	3 / 0
2026-10-05	Unavailable	Unavailable	3 / 0
2026-10-06	Unavailable	Unavailable	3 / 0
2026-10-07	Unavailable	Unavailable	3 / 0
2026-10-08	Unavailable	Unavailable	3 / 0
2026-10-09	Unavailable	Unavailable	3 / 0
2026-10-10	Unavailable	Unavailable	3 / 0
2026-10-11	Unavailable	Unavailable	3 / 0
2026-10-12	Unavailable	Unavailable	3 / 0
2026-10-13	Unavailable	Unavailable	3 / 0
2026-10-14	Unavailable	Unavailable	3 / 0
2026-10-15	Unavailable	Unavailable	3 / 0
2026-10-16	Unavailable	Unavailable	4 / 0

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	4	0	0
2026-06-01	5	0	0
2026-07-01	5	0	0
2026-08-01	5	0	0
2026-09-01	5	0	0
2026-10-01	6	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 6 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 17–Oct 16 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 17, 2026–Oct 16, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Sufficient cash reserves to fund operationsCash and cash equivalents: $237.366M
Advancement of HMB-001 and HMB-002 in clinical trialsDirect metric needs a verified mapping
Positive market reception of clinical dataDirect metric needs a verified mapping

Next proof point

Nov 10, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.3%Typical daily move · historical

Downside history

-48.4%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

HEMAB THERAPEUTICS HOLDINGS INC outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 10, 2026

What kind of bet this is

This investment represents a speculative growth opportunity in the healthcare sector. The current thesis is in a state of uncertainty due to recent earnings misses and management's focus on advancing clinical developments.

What's priced into HEMAB THERAPEUTICS HOLDINGS INC

The market appears to have low expectations priced in, as there are no signs of fragility in the current regime. However, the recent earnings miss and the overall high miss probability indicate that investors are cautious.

What the fundamentals likely do

Management is focused on advancing several clinical programs, which could provide a positive trajectory if successful. However, the high miss probability suggests that near-term performance may continue to be volatile.

What HEMAB THERAPEUTICS HOLDINGS INC hinges on

The thesis hinges on management's ability to execute on clinical developments and the overall health of the healthcare sector. Additionally, any cuts to guidance or worsening economic indicators could negatively impact sentiment.